Score one for tenacity. Exelixis (NASDAQ:EXEL) is up almost 50% today after releasing positive results from its phase 3 trial, dubbed Meteor, testing its drug Cometriq in patients with kidney cancer.
It’s been a long road to get here.
Cometriq
Like many biotechs, Exelixis started off going for the easier win, getting Cometriq approved in patients where there weren’t any other treatment options: medullary thyroid cancer.
Help employers find you! Check out all the jobs and post your resume.
